13/10/2017 09:54:16

Trinity Biotech plc to Announce 2017 Third Quarter Financial Results

DUBLIN, Ireland, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report 2017 third quarter financial results on Thursday, October 26, 2017. The Company has scheduled a conference call for that same day, Thursday, October 26, 2017 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:

USA:1-844-861-5499
International:1-412-317-6581
Conference ID #:10113410

A simultaneous webcast of the call can be accessed at:

https://www.webcaster4.com/Webcast/Page/1135/23066

A replay of the call can be accessed until November 2, 2017 by dialing:

USA:1-877-344-7529
International:1-412-317-0088
Conference ID #:10113410

The webcast of the call will be available for 30 days at: 

https://www.webcaster4.com/Webcast/Page/1135/23066

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Contact

Kevin Tansley

Trinity Biotech plc

(353)-1-2769800

E-mail: kevin.tansley@trinitybiotech.com

Joe Diaz, Joe Dorame and Robert Blum

Lytham Partners, LLC

Investor Relations

602-889-9700

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
10 Dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
13 Dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
24
08 Dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 Dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 Dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 Dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 Dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
07 Dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
09 Dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14
07 Dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14

Man Group PLC : Form 8.3 - [Ladbrokes Coral Group plc]

13/12/2017 15:01:16
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

Alliance Trust PLC : Net Asset Value(s)

13/12/2017 13:04:49
ALLIANCE TRUST PLC                                    At the close of business on Tuesday 12 December 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 791.0p -       including income, 794.4p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Investec Bank plc : Form 8.5 (EPT/RI) - Ladbrokes Coral Group plc

Related news
13/12/2017 09:50:50
 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sanofi : Sanofi presents R&D strategy and innovative pipeline
2
Rovio Entertainment Corp.: Share subscriptions based on stock options 2012B, 2012BII and 2015A
3
MGX Minerals to Acquire Zinc Air Battery Developer ZincNyx Energy Solutions
4
Scatec Solar secures a 40 MW PV project in Malaysia
5
Vornado Announces Public Offering of $450 Million 3.5% 7-Year Senior Unsecured Notes due 2025 and Calls for Redemption its $450 Million 2.5% Senior Unsecured Notes due 2019 and Calls for Redemption the Remaining $120 Million of its 6.625% Series I Cumulat

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
14 December 2017 05:59:57
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB7 - 2017-12-14 06:59:57 - 2017-12-14 05:59:57 - 1000 - Website: OKAY